Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 / 抑制剂/激动剂 / 膜转运蛋白 / P-gp / Tariquidar

他立喹达 /Tariquidar {[allProObj[0].p_purity_real_show]}

货号：A251517 同义名： XR9576

Tariquidar is a potent and selective noncompetitive inhibitor of P-glycoprotein with Kd of 5.1 nM, reverses drug resistance in MDR cell Lines.

Tariquidar 化学结构 CAS号：206873-63-4
Tariquidar 化学结构
CAS号：206873-63-4
Tariquidar 3D分子结构
CAS号：206873-63-4
Tariquidar 化学结构 CAS号：206873-63-4
Tariquidar 3D分子结构 CAS号：206873-63-4
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Tariquidar 纯度/质量文件 产品仅供科研

货号：A251517 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]
• JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]
• BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]
• J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]
• PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]
更多 >
产品名称 P-gp ↓ 其他靶点 纯度
Elacridar ✔ BCRP 99%+
Zosuquidar 3HCl ++

P-gp, Ki: 60 nM

 		99%+
SC144 ✔ 99%+
Tariquidar +++

P-gp, Kd: 5.1 nM

 		98%
Schizandrin B ✔ 98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Tariquidar 生物活性

靶点

  • P-gp

    P-gp, Kd:5.1 nM
描述 The multidrug resistance is an obstacle in the chemotherapy treatment (such as doxorubicin, vincristine, paclitaxel, TKIs) for many solid and haematological tumours. Many factors can cause the multidrug resistance. Among them, the overexpression of P-gp (ABCB1), of which vinblastine and paclitaxel is the substrate, on the surface of resistant cells is considered as a key factor mediating multidrug resistance. Thus, the increased bioavailable and brain accumulation of anticancer drugs can be achieved partially through inhibition of P-gp. Tariquidar is a potent P-gp transport modulator with IC50 value of 0.4μM, displaying specific high-affinity binding to P-gp with Kd of 5.1nM. The cellular study showed that the accumulation of vinblastine and paclitaxel can be increased in a dose-dependent manner by tariquidar with EC50 value of 487nM and 25.4nM, respectively, in CHrB30 cells, not mediated through competition for transport[1]. Co-administration of paclitaxel with tariquidar (p.o., 50mg/kg) led to a comparable increase and a long lasting 5-fold increase in the concentration of paclitaxel accumulation in the cytostatic in the brain of nude mice[2].
作用机制 Tariquidar can bind at a site which is distinct from the site of interaction of transport substrates and alter P-gp-mediated transport by affecting its rate of ATP hydrolysis.[1]

Tariquidar 细胞研究

细胞系 浓度 检测类型 检测时间 活动说明 数据源
A2780 cells Function assay 30 mins Inhibition of human Pgp in A2780 cells after 30 mins by Hoechst 33342 assay, IC50=0.12589 μM 18083034
EMT6/AR1.0 cells Function assay 1 h Inhibition of mouse Pgp in EMT6/AR1.0 cells after 1 hr by daunorubicin accumulation assay, IC50=0.064 μM 18083034
human CCD-18Co cells Cytotoxic assay 48 h Cytotoxicity against human CCD-18Co cells assessed as cell viability after 48 hrs by MTT assay, IC50=25 μM 26197160
human CEM/VLB500 cells Function assay 3 days Reversal of P-gp-mediated multidrug resistance to vinblastine in human CEM/VLB500 cells after 3 days by resazurin assay, EC50=0.068 μM 17399990

Tariquidar 动物研究

Dose Rat[3] (i.v.): 1 mg/kg - 15 mg/kg; Mice[4] (i.p.): 6.5 mg/kg - 13 mg/kg; Mice[5] (p.o.): 6 mg/kg - 12 mg/kg
Administration i.v., i.p., p.o.
Pharmacokinetics
Animal Rats[6]
Dose 15 mg/kg
Administration i.v.
p.o.
i.p.
F 71.6% (p.o.)
91.4% (i.p.)
AUC0→24h 25.2 μg·h/ml (i.v.)
18.1 μg·h/ml (p.o.)
23.8 μg·h/ml (i.p.)
Tmax 0.5 μg/ml (i.v.)
4.0 μg/ml (p.o.)
2.0 μg/ml (i.p.)
Cmax 1.9 μg/ml (i.v.)
1.2 μg/ml (p.o.)
1.5 μg/ml (i.p.)

Tariquidar 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01663545 - Completed - United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT01547754 - Terminated - United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT01386476 - Completed - United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<

Tariquidar 参考文献

[1]Hubensack M, M¨¹ller C, et al. Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. J Cancer Res Clin Oncol. 2008 May;134(5):597-607. Epub 2007 Oct 12.

[2]Martin C, Berridge G, et al. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol. 1999 Sep;128(2):403-11

[3]Bankstahl JP, Kuntner C, et al. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. J Nucl Med. 2008 Aug;49(8):1328-35.

[4]Foran E, Kwon DY, et al. CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy. Neurobiol Dis. 2016 Apr;88:118-24.

[5]Mistry P, Stewart AJ, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res. 2001 Jan 15;61(2):749-58.

[6]Matzneller P, Kussmann M, et al. Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration. Eur J Drug Metab Pharmacokinet. 2018 Oct;43(5):599-606.

Tariquidar 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.55mL

0.31mL

0.15mL

7.73mL

1.55mL

0.77mL

15.46mL

3.09mL

1.55mL

Tariquidar 技术信息

CAS号206873-63-4
分子式C38H38N4O6
分子量 646.731
别名 XR9576
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Sealed in dry,2-8°C
溶解度

DMSO: 15 mg/mL(23.19 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方

IP 3% DMSO+3% Tween80+40% PEG300+water 1 mg/mL clear

PO 0.5% CMC-Na 60 mg/mL suspension

Tags: Tariquidar | 206873-63-4 | XR9576 | XR 9576 | XR-9576 | P-gp Inhibitor | Membrane Transporter/Ion Channel | P-glycoprotein | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | Tariquidar 纯度/质量文件 | Tariquidar 亚型比较 | Tariquidar 生物活性 | Tariquidar 细胞研究 | Tariquidar 动物研究 | Tariquidar 临床数据 | Tariquidar 参考文献 | Tariquidar 实验方案 | Tariquidar 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z